Where is Aurobindo Pharma headquartered?

The company is headquartered in Hyderabad, Telangana, India. It also runs a US arm headquartered in East Windsor, New Jersey.

Who leads Aurobindo Pharma?

K. Nityananda Reddy is Vice Chairman and Managing Director. Mangalam Ramasubramanian Kumar is the Non-Executive Chairman, and Subramanian Santhanam is Chief Financial Officer.

Is Aurobindo Pharma publicly listed?

Yes. It trades as AUROPHARMA on the NSE and under code 524804 on the BSE, with market capitalization near Rs 91,749 crore as of July 2026.

How many people work at Aurobindo Pharma?

LinkedIn lists Aurobindo Pharma in the 10,001+ employees band. The company hires across production, quality, engineering and research functions.

What is the interview process like at Aurobindo Pharma?

Candidates rate the experience around 7 out of 10 with a Medium difficulty of about 6 out of 10. Most processes run from a day or two up to about a month.

What roles does Aurobindo Pharma hire for?

Active hiring covers Production, Packing, Quality Assurance, Quality Control, Microbiology and Engineering, largely through walk-in drives at its Andhra Pradesh and Telangana units.

Aurobindo Pharma Careers

Q: When was Aurobindo Pharma founded?

Aurobindo Pharma was founded in 1986 by V. Ramprasad Reddy and K. Nityananda Reddy, and was incorporated on 26 December 1986.

Hyderabad-based Indian multinational maker of generic drugs, APIs, biologics and vaccines, sold in over 150 countries.

aurobindo.com

About the company

Founded

1986

Headquarters

Hyderabad, Telangana, India

Industry

Pharmaceuticals

Employees

10,001+

Revenue (FY26)

Rs 33,653 crore

Market Cap

Rs 91,749 crore

Listed on

NSE: AUROPHARMA, BSE: 524804

Managing Director

K. Nityananda Reddy

Website

aurobindo.com

CIN

L24239TG1986PLC015190

Aurobindo Pharma Limited is an Indian multinational pharmaceutical company headquartered in Hyderabad, Telangana. It was founded in 1986 by V. Ramprasad Reddy and K. Nityananda Reddy and incorporated on 26 December 1986. The company makes generic drugs, active pharmaceutical ingredients, biologics, vaccines and related products, and sells across more than 150 countries.

The company is publicly listed in India, trading as AUROPHARMA on the NSE and under code 524804 on the BSE, with corporate identification number L24239TG1986PLC015190. For the fiscal year ended March 2026 it reported consolidated revenue of about Rs 33,653 crore, and its market capitalization stood near Rs 91,749 crore as of 21 July 2026.

Leadership sits with Vice Chairman and Managing Director K. Nityananda Reddy, who has led operations since the company's founding. Mangalam Ramasubramanian Kumar serves as Independent Director and Non-Executive Chairman, Subramanian Santhanam is Chief Financial Officer, and M. Madan Mohan Reddy is a Whole-time Director. Alongside its Hyderabad base, the company runs a US arm headquartered in East Windsor, New Jersey.

Key People

K. Nityananda Reddy

Vice Chairman & Managing Director

Mangalam Ramasubramanian Kumar

Independent Director & Non-Executive Chairman

Subramanian Santhanam

Chief Financial Officer

M. Madan Mohan Reddy

Whole-time Director

Photos

Interview process at Aurobindo Pharma

(225 interview reviews)

Interview experience

Favourable (7 out of 10)

Interview difficulty

Medium (6 out of 10)

Interview process length

About a day to a month

Overall experience

PoorExcellent

EasyDifficult

How long does the process take?

About a day or two29%

About a week25%

About a month31%

More than one month15%

See all Aurobindo Pharma interview questions & answers

Browse question banks by role, round and company, with answers and examples.

Aurobindo Pharma Salaries in India (Updated 2026)

Technical Assistant

1 to 8 yrs

₹3.8L to ₹4.2L/yr

1,000 Salaries submitted

Research Associate

0 to 9 yrs

₹5.4L to ₹5.9L/yr

242 Salaries submitted

Executive Production

1 to 13 yrs

₹5.6L to ₹6.3L/yr

182 Salaries submitted

Executive Engineer

1 to 10 yrs

₹5.2L to ₹5.7L/yr

165 Salaries submitted

Senior Chemist

5 to 12 yrs

₹5L to ₹5.5L/yr

142 Salaries submitted

QA Executive

1 to 10 yrs

₹5.1L to ₹5.7L/yr

128 Salaries submitted

Know your worth at Aurobindo Pharma

Compare your salary against real submissions and open roles.

Open roles

Executive - Production (OSD)

2 to 6 years • Naidupeta, Andhra Pradesh • Full-time

Technical Assistant - Packing (OSD)

2 to 8 years • Naidupeta, Andhra Pradesh • Full-time

Executive - Quality Control

2 to 8 years • Naidupeta, Andhra Pradesh • Full-time

Executive - Quality Assurance

2 to 8 years • Naidupeta, Andhra Pradesh • Full-time

Executive - Engineering (Instrumentation & Automation)

4 to 8 years • Naidupeta, Andhra Pradesh • Full-time

Executive - Production

3 to 8 years • Jadcherla, Telangana • Full-time

Get ready for an AI interview

Free guides to AI video screens, coding tests and how scoring works.

Benefits

Health and wellness support (medical benefits), reported by 266 employees

Group medical and health insurance, employees cite around Rs 2 LPA coverage

Learning and development and training support, reported by 278 employees

Transport and travel (cab) support, reported by 196 employees

Free meals and subsidised canteen, reported by 69 employees

Flexible shift timing

Performance bonus, reported by 13 employees

Annual bonus (company average around Rs 31,000)

Relocation assistance

Paid annual leave, employees report around 30 days

Latest News & Updates

July 13, 2026

Aurobindo subsidiary incorporates PT Auro Pharm Indonesia

Aurobindo's step-down subsidiary PT Aurogen Pharma Indonesia incorporated a new wholly owned manufacturing entity, PT Auro Pharm Indonesia, on July 1, 2026 with an initial IDR 20 billion investment. The move expands the company's manufacturing footprint in Indonesia.

#expansion #manufacturing #Indonesia

View post

May 21, 2026

Aurobindo Q4 FY26 net profit up 2% to Rs 921 crore

Consolidated net profit rose about 2% year on year to Rs 921 crore in the March 2026 quarter, with revenue from operations up 5.6% to Rs 8,853 crore. Full-year FY26 revenue crossed Rs 33,653 crore, up 6.1%.

#earnings #Q4FY26 #results

View post

May 7, 2026

Aurobindo completes Rs 800 crore share buyback

The company completed its tender-route buyback of 54,23,728 equity shares at Rs 1,475 per share, utilising about Rs 800 crore. The offer was oversubscribed roughly 5.43 times.

#buyback #capitalreturn #shareholders

View post

May 1, 2026

CuraTeQ's Bevqolva biosimilar gets Health Canada nod

Aurobindo's subsidiary CuraTeQ Biologics received a Notice of Compliance from Health Canada for Bevqolva, a bevacizumab biosimilar to Avastin, in 100 mg and 400 mg presentations. Two further biosimilar applications remain under review with Health Canada.

#biosimilars #regulatory #Canada

View post

April 17, 2026

Aurobindo wins USFDA nod for generic Ravicti

The company received USFDA final approval for Glycerol Phenylbutyrate Oral Liquid 1.1 g/mL, a generic of Horizon Therapeutics' Ravicti used for urea cycle disorders. The product carries an estimated US market size of about USD 50.2 million.

#USFDA #approval #generics

View post

See all updates

Aurobindo Pharma FAQ

Aurobindo Pharma makes generic drugs, active pharmaceutical ingredients, biologics and vaccines. It sells across more than 150 countries from its base in Hyderabad, India.